ULK1 inhibition overcomes compromised antigen presentation and restores antitumor immunity in LKB1-mutant lung cancer

Inactivating mutations in LKB1/STK11 are present in roughly 20% of nonsmall cell lung cancers (NSCLC) and portend poor response to anti-PD-1 immunotherapy. Unexpectedly, we found that LKB1 deficiency correlated with elevated tumor mutational burden (TMB) in NSCLCs from nonsmokers and genetically eng...

Full description

Bibliographic Details

Published in:	Nature cancer Vol. 2; no. 5; pp. 503 - 514
Main Authors:	Deng, Jiehui, Thennavan, Aatish, Dolgalev, Igor, Chen, Ting, Li, Jie, Marzio, Antonio, Poirier, John T., Peng, David H., Bulatovic, Mirna, Mukhopadhyay, Subhadip, Silver, Heather, Papadopoulos, Eleni, Pyon, Val, Thakurdin, Cassandra, Han, Han, Li, Fei, Li, Shuai, Ding, Hailin, Hu, Hai, Pan, Yuanwang, Weerasekara, Vajira, Jiang, Baishan, Wang, Eric S., Ahearn, Ian, Philips, Mark, Papagiannakopoulos, Thales, Tsirigos, Aristotelis, Rothenberg, Eli, Gainor, Justin, Freeman, Gordon J., Rudin, Charles M., Gray, Nathanael S., Hammerman, Peter S., Pagano, Michele, Heymach, John V., Perou, Charles M., Bardeesy, Nabeel, Wong, Kwok-Kin
Format:	Journal Article
Language:	English
Published:	England Nature Publishing Group 01.05.2021
Subjects:	Antigen Presentation Autophagy-Related Protein-1 Homolog - genetics Carcinoma, Non-Small-Cell Lung - drug therapy Cell cycle DNA repair Experiments Humans Intracellular Signaling Peptides and Proteins Kinases Lung cancer Lung Neoplasms - drug therapy Mutation Phosphorylation Recruitment Tumors
ISSN:	2662-1347, 2662-1347
Online Access:	Get full text
Tags:	Add Tag No Tags, Be the first to tag this record!